- IPC GENERAL
- IPC News
Honoring Professor Hervé Bachelez, MD, PhD, as He Concludes His Service on the IPC Board
The International Psoriasis Council (IPC) extends its sincere appreciation to Hervé Bachelez, MD, PhD, as he concludes his service on the IPC Board of Directors. Professor Bachelez has been a central figure in IPC leadership for many years, serving as Board member, Secretary, Vice President, President, and Immediate Past President. Following the conclusion of his presidential term, he remained on the Board for an additional year, continuing to provide guidance, continuity, and strategic perspective.
Leadership During a Period of Growth
During his presidency, Professor Bachelez helped guide IPC through a period of meaningful progress, including the organization’s 20th anniversary. His term was marked by expanded participation in IPC educational programs, strengthened global engagement, and continued advancement across research, education, and collaborative initiatives focused on improving psoriasis care worldwide. These efforts reflected close collaboration across IPC’s Board, Councilors, Fellows, staff, and corporate partners, reinforcing IPC’s role as a global professional community.
Professor Bachelez also supported the implementation of IPC’s long-term strategic plan, helping position the organization for continued growth while emphasizing transparency, inclusivity, and rigorous scientific exchange.
Continued Engagement With IPC
In addition to his leadership roles, Professor Bachelez consistently brought deep scientific expertise and clinical insight to IPC’s work as an internationally recognized clinician-scientist. His contributions helped ensure that IPC initiatives remained grounded in evidence-based care and global relevance.
While Professor Bachelez has now concluded his term on the IPC Board, he will continue to serve the organization as a Councilor, remaining actively engaged in IPC’s mission and community.
We thank Professor Bachelez for his years of dedicated service, leadership, and commitment to advancing psoriasis research and patient care worldwide. His impact on IPC will continue well beyond his Board service.
